# Alessandra Moretti

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 78 papers | 5,863 citations | 32 h-index | 76 g-index |
| 93 ext. papers | 6,669 ext. citations | 9.5 avg, IF | 4.92 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 78 | Endothelial Retargeting of AAV9 In Vivo.. *Advanced Science*, **2022**, e2103867 | 13.6 | 1 |
| 77 | MicroRNA-365 regulates human cardiac action potential duration.. *Nature Communications*, **2022**, 13, 220 | 17.4 | 3 |
| 76 | Cell cycle defects underlie childhood-onset cardiomyopathy associated with Noonan syndrome.. *IScience*, **2022**, 25, 103596 | 6.1 | 0 |
| 75 | Nicht kodierende Ribonukleinsäure im kardiovaskulären System. *Kardiologe*, **2022**, 16, 100-108 | 0.6 | |
| 74 | Generation of heterozygous (MRli003-A-3) and homozygous (MRli003-A-4) TRPM4 knockout human iPSC lines.. *Stem Cell Research*, **2022**, 60, 102731 | 1.6 | |
| 73 | Generation of heterozygous (MRli003-A-5) and homozygous (MRli003-A-6) voltage-sensing knock-in human iPSC lines by CRISPR/Cas9 editing of the AAVS1 locus.. *Stem Cell Research*, **2022**, 61, 102785 | 1.6 | 0 |
| 72 | Generation of two human iPSC lines, HMGUi003-A and MRIi028-A, carrying pathogenic biallelic variants in the PPCS gene.. *Stem Cell Research*, **2022**, 61, 102773 | 1.6 | 1 |
| 71 | Use of hiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19.. *Frontiers in Physiology*, **2021**, 12, 730127 | 4.6 | 0 |
| 70 | Truncated titin proteins and titin haploinsufficiency are targets for functional recovery in human cardiomyopathy due to mutations. *Science Translational Medicine*, **2021**, 13, eabd3079 | 17.5 | 6 |
| 69 | Innervated mouse pancreas organoids as an model to study pancreatic neuropathy in pancreatic cancer. *STAR Protocols*, **2021**, 2, 100935 | 1.4 | 1 |
| 68 | Generation of heterozygous (MRli003-A-1) and homozygous (MRli003-A-2) MYH10 knockout human iPSC lines. *Stem Cell Research*, **2021**, 57, 102612 | 1.6 | |
| 67 | Deciphering the Role of Wnt and Rho Signaling Pathway in iPSC-Derived ARVC Cardiomyocytes by In Silico Mathematical Modeling. *International Journal of Molecular Sciences*, **2021**, 22, | 6.3 | 1 |
| 66 | Sequential Defects in Cardiac Lineage Commitment and Maturation Cause Hypoplastic Left Heart Syndrome. *Circulation*, **2021**, 144, 1409-1428 | 16.7 | 6 |
| 65 | AntimiR-132 Attenuates Myocardial Hypertrophy in an Animal Model of Percutaneous Aortic Constriction. *Journal of the American College of Cardiology*, **2021**, 77, 2923-2935 | 15.1 | 11 |
| 64 | Human BIN1 isoforms grow, maintain and regenerate excitation-contraction couplons in adult rat and human stem cell-derived cardiomyocytes. *Cardiovascular Research*, **2021**, | 9.9 | 2 |
| 63 | Progressive stretch enhances growth and maturation of 3D stem-cell-derived myocardium. *Theranostics*, **2021**, 11, 6138-6153 | 12.1 | 7 |
| 62 | Genome editing for Duchenne muscular dystrophy: a glimpse of the future?. *Gene Therapy*, **2021**, 28, 542-548 | 4 | 7 |

| | | | |
|---|---|---|---|
| 61 | Approved drugs ezetimibe and disulfiram enhance mitochondrial Ca uptake and suppress cardiac arrhythmogenesis. *British Journal of Pharmacology*, **2021**, 178, 4518-4532 | 8.6 | 3 |
| 60 | DGK and DZHK position paper on genome editing: basic science applications and future perspective. *Basic Research in Cardiology*, **2021**, 116, 2 | 11.8 | 2 |
| 59 | Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy. *Nature Medicine*, **2020**, 26, 207-214 | 50.5 | 85 |
| 58 | Precise Correction of Heterozygous SHOX2 Mutations in hiPSCs Derived from Patients with Atrial Fibrillation via Genome Editing and Sib Selection. *Stem Cell Reports*, **2020**, 15, 999-1013 | 8 | 1 |
| 57 | Domain zipping and unzipping modulates TRPM4's properties in human cardiac conduction disease. *FASEB Journal*, **2020**, 34, 12114-12126 | 0.9 | 3 |
| 56 | Transcriptome Analysis of Reticulated Platelets Reveals a Prothrombotic Profile. *Thrombosis and Haemostasis*, **2019**, 119, 1795-1806 | 7 | 27 |
| 55 | Human Induced Pluripotent Stem Cells as Platform for Functional Examination of Cardiovascular Genetics in a Dish. *Cardiac and Vascular Biology*, **2019**, 341-357 | 0.2 | |
| 54 | The Wnt inhibitor Dkk1 is required for maintaining the normal cardiac differentiation program in Xenopus laevis. *Developmental Biology*, **2019**, 449, 1-13 | 3.1 | 10 |
| 53 | Aberrant Deactivation-Induced Gain of Function in TRPM4 Mutant Is Associated with Human Cardiac Conduction Block. *Cell Reports*, **2018**, 24, 724-731 | 10.6 | 9 |
| 52 | Identification of Differentially Regulated Pathways in Cardiac Development and Cardiac Gene Expression during In Vitro Cardiac Differentiation of HLHS-derived Human Induced Pluripotent Stem Cells using Transcriptome Analysis. *Thoracic and Cardiovascular Surgeon*, **2018**, 66, S1-S110 | 1.6 | |
| 51 | Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Towards Personalized Therapeutic Strategies?. *Cardiac and Vascular Biology*, **2018**, 421-437 | 0.2 | |
| 50 | Subtype-specific Optical Action Potential Recordings in Human Induced Pluripotent Stem Cell-derived Ventricular Cardiomyocytes. *Journal of Visualized Experiments*, **2018**, | 1.6 | 1 |
| 49 | Functional abnormalities in induced Pluripotent Stem Cell-derived cardiomyocytes generated from titin-mutated patients with dilated cardiomyopathy. *PLoS ONE*, **2018**, 13, e0205719 | 3.7 | 24 |
| 48 | Interplay of cell-cell contacts and RhoA/MRTF-A signaling regulates cardiomyocyte identity. *EMBO Journal*, **2018**, 37, | 13 | 46 |
| 47 | Diabetes Mellitus-Induced Microvascular Destabilization in the Myocardium. *Journal of the American College of Cardiology*, **2017**, 69, 131-143 | 15.1 | 77 |
| 46 | Perspectives and Challenges of Pluripotent Stem Cells in Cardiac Arrhythmia Research. *Current Cardiology Reports*, **2017**, 19, 23 | 4.2 | 8 |
| 45 | Subtype-specific promoter-driven action potential imaging for precise disease modelling and drug testing in hiPSC-derived cardiomyocytes. *European Heart Journal*, **2017**, 38, 292-301 | 9.5 | 49 |
| 44 | Suppression of Arrhythmia by Enhancing Mitochondrial Ca Uptake in Catecholaminergic Ventricular Tachycardia Models. *JACC Basic To Translational Science*, **2017**, 2, 737-747 | 8.7 | 26 |

| | | | |
|---|---|---|---|
| 43 | Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes. *Cardiovascular Research*, **2017**, 113, 531-541 | 9.9 | 79 |
| 42 | Human Engineered Heart Tissue: Analysis of Contractile Force. *Stem Cell Reports*, **2016**, 7, 29-42 | 8 | 217 |
| 41 | A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells. *EMBO Molecular Medicine*, **2016**, 8, 1065-81 | 12 | 66 |
| 40 | Induced Pluripotent Stem Cells in Regenerative Medicine **2016**, 51-75 | | 1 |
| 39 | Direct nkx2-5 transcriptional repression of isl1 controls cardiomyocyte subtype identity. *Stem Cells*, **2015**, 33, 1113-29 | 5.8 | 63 |
| 38 | Live fluorescent RNA-based detection of pluripotency gene expression in embryonic and induced pluripotent stem cells of different species. *Stem Cells*, **2015**, 33, 392-402 | 5.8 | 20 |
| 37 | Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy. *EMBO Molecular Medicine*, **2015**, 7, 562-76 | 12 | 74 |
| 36 | Genetically Encoded Voltage Indicators in Circulation Research. *International Journal of Molecular Sciences*, **2015**, 16, 21626-42 | 6.3 | 18 |
| 35 | Functional comparison of induced pluripotent stem cell- and blood-derived GPIIbIIIa deficient platelets. *PLoS ONE*, **2015**, 10, e0115978 | 3.7 | 13 |
| 34 | Automated analysis of contractile force and Ca2+ transients in engineered heart tissue. *American Journal of Physiology - Heart and Circulatory Physiology*, **2014**, 306, H1353-63 | 5.2 | 60 |
| 33 | Induced pluripotent stem cell-derived cardiomyocytes for drug development and toxicity testing. *Pharmacology & Therapeutics*, **2014**, 143, 246-52 | 13.9 | 72 |
| 32 | Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. *EMBO Journal*, **2013**, 32, 3161-75 | 13 | 145 |
| 31 | Pluripotent stem cell models of human heart disease. *Cold Spring Harbor Perspectives in Medicine*, **2013**, 3, | 5.4 | 61 |
| 30 | Modeling long-QT syndromes with iPS cells. *Journal of Cardiovascular Translational Research*, **2013**, 6, 31-6 | 3.3 | 17 |
| 29 | Treatment of Patients with Long-QT Syndrome: Differentiation of Patient-Derived Induced Pluripotent Stem Cells into Functional Cardiac Myocytes **2013**, 93-100 | | |
| 28 | Embryonic heart progenitors and cardiogenesis. *Cold Spring Harbor Perspectives in Medicine*, **2013**, 3, a013847 | 5.4 | 133 |
| 27 | In vitro generation of hiPSC-derived megakaryocytes and platelets from a patient with Glanzmann thrombasthenia. *European Heart Journal*, **2013**, 34, 5867-5867 | 9.5 | |
| 26 | Induced pluripotent stem cell-derived cardiomyocytes: a versatile tool for arrhythmia research. *Circulation Research*, **2013**, 112, 961-8 | 15.7 | 40 |

| | | | |
|---|---|---|---|
| 25 | Modeling Arrhythmogenic Heart Disease with Patient-Specific Induced Pluripotent Stem Cells **2013**, 276-304 | | |
| 24 | Induced pluripotent stem cells in cardiovascular research. *Reviews of Physiology, Biochemistry and Pharmacology*, **2012**, 163, 1-26 | 2.9 | 6 |
| 23 | Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. *EMBO Molecular Medicine*, **2012**, 4, 180-91 | 12 | 257 |
| 22 | Recapitulating long-QT syndrome using induced pluripotent stem cell technology. *Pediatric Cardiology*, **2012**, 33, 950-8 | 2.1 | 8 |
| 21 | Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 11866-71 | 11.5 | 45 |
| 20 | Mouse and human induced pluripotent stem cells as a source for multipotent Isl1+ cardiovascular progenitors. *FASEB Journal*, **2010**, 24, 700-11 | 0.9 | 100 |
| 19 | Patient-specific induced pluripotent stem-cell models for long-QT syndrome. *New England Journal of Medicine*, **2010**, 363, 1397-409 | 59.2 | 943 |
| 18 | Neuropotent self-renewing neural stem (NS) cells derived from mouse induced pluripotent stem (iPS) cells. *Molecular and Cellular Neurosciences*, **2010**, 43, 287-95 | 4.8 | 47 |
| 17 | MicroRNAs in a cardiac loop: progenitor or myocyte?. *Developmental Cell*, **2010**, 19, 787-8 | 10.2 | 2 |
| 16 | Multipotent progenitor cells in regenerative cardiovascular medicine. *Pediatric Cardiology*, **2009**, 30, 690-8 | 2.1 | 23 |
| 15 | Islet1 cardiovascular progenitors: a single source for heart lineages?. *Development (Cambridge)*, **2008**, 135, 193-205 | 6.6 | 186 |
| 14 | Biology of Isl1+ cardiac progenitor cells in development and disease. *Cellular and Molecular Life Sciences*, **2007**, 64, 674-82 | 10.3 | 32 |
| 13 | The renewal and differentiation of Isl1+ cardiovascular progenitors are controlled by a Wnt/beta-catenin pathway. *Cell Stem Cell*, **2007**, 1, 165-79 | 18 | 268 |
| 12 | Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. *Cell*, **2006**, 127, 1151-65 | 56.2 | 812 |
| 11 | Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. *Nature*, **2005**, 433, 647-53 | 50.4 | 1087 |
| 10 | Gene transfer of the pancaspase inhibitor P35 reduces myocardial infarct size and improves cardiac function. *Journal of Molecular Medicine*, **2005**, 83, 526-34 | 5.5 | 12 |
| 9 | Development. ES cells to the rescue. *Science*, **2004**, 306, 239-40 | 33.3 | 34 |
| 8 | Effects of two Gbetagamma-binding proteins--N-terminally truncated phosducin and beta-adrenergic receptor kinase C terminus (betaARKct)--in heart failure. *Gene Therapy*, **2003**, 10, 1354-61 | 4 | 33 |

| | | | |
|---|---|---|---|
| 7 | Essential myosin light chain as a target for caspase-3 in failing myocardium. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 11860-5 | 11.5 | 88 |
| 6 | Blocking caspase-activated apoptosis improves contractility in failing myocardium. *Human Gene Therapy*, **2001**, 12, 2051-63 | 4.8 | 78 |
| 5 | Gene transfer of heterologous G protein-coupled receptors to cardiomyocytes: differential effects on contractility. *Circulation Research*, **2001**, 88, 688-95 | 15.7 | 9 |
| 4 | Enhanced cardiac contractility after gene transfer of V2 vasopressin receptors In vivo by ultrasound-guided injection or transcoronary delivery. *Circulation*, **2000**, 101, 1578-85 | 16.7 | 61 |
| 3 | Adenoviral gene transfer of the human V2 vasopressin receptor improves contractile force of rat cardiomyocytes. *Circulation*, **1999**, 99, 925-33 | 16.7 | 23 |
| 2 | Functional diversity of P-type and R-type calcium channels in rat cerebellar neurons. *Journal of Neuroscience*, **1996**, 16, 6353-63 | 6.6 | 154 |
| 1 | Three novel types of voltage-dependent calcium channels in rat cerebellar neurons. *Journal of Neuroscience*, **1994**, 14, 5243-56 | 6.6 | 50 |